China Pharma Holdings, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 26, 2021. This is an annual report, not a standalone fourth-quarter report, and the filing does not provide clear Q4-only financial results. The company develops, manufactures and sells pharmaceuticals in China, primarily prescription generics, and also sells healthcare and protective products.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $10.87 million | $10.92 million |
| Gross profit / margin | $1.95 million / 18.0% | $1.48 million / 13.6% |
| Operating loss | $2.58 million | $20.41 million |
| Net loss | $2.87 million | $20.70 million |
| Basic and diluted loss per share | $0.07 | $0.48 |
| Cash from operations | Used $42,000 | Provided $608,000 |
- Revenue was nearly flat overall, but included $1.73 million from a one-time export transaction of COVID-19 diagnostic testers. Domestic pharmaceutical revenue fell to $9.13 million from $10.92 million, a decline of about 16%.
- Gross margin improved mainly due to the tester transaction and government relief for employee social-insurance costs. Selling and G&A expenses declined; R&D expense increased to $378,000, primarily for generic-drug consistency evaluations.
- The net loss narrowed sharply because 2019 included a $17.02 million impairment charge on advances for drug-formula development. There was no impairment loss in 2020.
- Investing activities used $867,000, mainly for mask-production lines. Financing activities provided $624,000, including new bank borrowings. Cash and cash equivalents ended the year at $958,000, down from $1.07 million; cash including restricted cash was $958,000 versus $1.18 million.
- Total assets were $21.12 million and total liabilities $13.11 million. Current assets of $5.32 million were below current liabilities of $11.40 million, implying net current liabilities of about $6.08 million. Total stockholders’ equity was $8.00 million.
- Debt included $2.30 million of current construction-loan principal and $2.94 million of credit lines, of which $904,000 was classified as noncurrent. Related-party borrowings were $2.13 million. The filing’s loan maturity table appears to reverse the labels for construction debt and lines of credit; verify the classification against the underlying notes.
Material changes and unusual items
- Sales of existing pharmaceuticals declined amid COVID-19-related disruption, including temporary facility closures, staff quarantine and reduced hospital outpatient activity. Operations returned to normal in the second quarter, according to the company.
- Centralized procurement and tighter drug-price controls contributed to lower sales of products including Roxithromycin, Ozagrel, Vitamin B6 and Omeprazole.
- Two million shares were issued to the CEO in December 2020 in partial conversion of $864,480 in unpaid compensation. Shares outstanding increased from 43.58 million to 45.58 million.
- Accounts receivable were $502,000 net of an $18.15 million allowance. The filing reports that 96.98% of receivables were more than 720 days old, highlighting significant collection and estimation risk despite the relatively small net balance.
Outlook, risks and contingencies
- The independent auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses, net current liabilities and accumulated deficit. Management expects continued operating losses.
- Management’s plans include seeking advance customer payments, strengthening collections, accelerating nutrition-product launches and using fixed assets as collateral for additional loans. Management states current resources may fund operations for 12 months, but the plans are not assured; the financial statements include no adjustments for a possible failure to continue as a going concern.
- COVID-19, intense competition, price reductions from centralized procurement, generic-drug consistency-evaluation requirements, product approvals and regulatory inspections could affect sales or production. Failure to meet inspection requirements could result in production suspension.
- Operations and substantially all revenue are in China. Currency conversion and remittances are restricted, and exchange-rate, PRC regulatory, political and legal risks may affect the company and its ability to transfer funds to its U.S. parent.
- Three customers represented 52.0%, 11.2% and 10.2% of year-end accounts receivable; one customer accounted for 16.0% of 2020 sales. Three suppliers represented 20.7%, 17.7% and 13.5% of raw-material purchases.
- Management concluded internal control over financial reporting was ineffective at year-end because of a material weakness involving insufficient personnel knowledgeable in U.S. GAAP. The company reported no material legal proceedings known to it and no off-balance-sheet arrangements.
Investor facts to verify
- Whether operating cash flow, customer collections and available financing can cover near-term obligations, especially approximately $4.34 million of current bank principal shown on the balance sheet.
- The recoverability and aging of receivables, adequacy of the $18.15 million allowance, and exposure to the customers with large outstanding balances.
- Whether recurring pharmaceutical sales stabilize without further one-time COVID-19 product revenue, and how centralized procurement affects prices, volumes and margins.
- Progress and costs of consistency evaluations, NMPA approvals and production-line inspections, including the product that passed bioequivalence experiments in March 2021.
- The apparent inconsistency in the filing’s gross-margin discussion: the financial statements and MD&A report 18.0% for 2020, while a risk-factor passage cites 17.0%.
- Remediation of the material weakness and the effect of the 2.0 million-share compensation conversion on ownership and dilution.